Cargando…

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville...

Descripción completa

Detalles Bibliográficos
Autores principales: Torka, Pallawi, Pederson, Levi D., Knopp, Michael V., Poon, David, Zhang, Jun, Kahl, Brad S., Higley, Howard R., Kelloff, Gary, Friedberg, Jonathan W., Schwartz, Lawrence H., Wilson, Wyndham H., Leonard, John P., Bartlett, Nancy L., Schöder, Heiko, Ruppert, Amy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134372/
https://www.ncbi.nlm.nih.gov/pubmed/36799072
http://dx.doi.org/10.1002/cam4.5628
_version_ 1785031749894406144
author Torka, Pallawi
Pederson, Levi D.
Knopp, Michael V.
Poon, David
Zhang, Jun
Kahl, Brad S.
Higley, Howard R.
Kelloff, Gary
Friedberg, Jonathan W.
Schwartz, Lawrence H.
Wilson, Wyndham H.
Leonard, John P.
Bartlett, Nancy L.
Schöder, Heiko
Ruppert, Amy S.
author_facet Torka, Pallawi
Pederson, Levi D.
Knopp, Michael V.
Poon, David
Zhang, Jun
Kahl, Brad S.
Higley, Howard R.
Kelloff, Gary
Friedberg, Jonathan W.
Schwartz, Lawrence H.
Wilson, Wyndham H.
Leonard, John P.
Bartlett, Nancy L.
Schöder, Heiko
Ruppert, Amy S.
author_sort Torka, Pallawi
collection PubMed
description BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS). METHODS: In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes. RESULTS: Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (<66% vs. ≥66%). ∆SUV ≥66% at iPET was significantly associated with PFS (p = 0.03) and OS (p = 0.002), but VSS was not. Associations with PFS/OS when applying local review vs central review were comparable. CONCLUSIONS: These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials.
format Online
Article
Text
id pubmed-10134372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101343722023-04-28 Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis Torka, Pallawi Pederson, Levi D. Knopp, Michael V. Poon, David Zhang, Jun Kahl, Brad S. Higley, Howard R. Kelloff, Gary Friedberg, Jonathan W. Schwartz, Lawrence H. Wilson, Wyndham H. Leonard, John P. Bartlett, Nancy L. Schöder, Heiko Ruppert, Amy S. Cancer Med BRIEF COMMUNICATION BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS). METHODS: In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes. RESULTS: Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (<66% vs. ≥66%). ∆SUV ≥66% at iPET was significantly associated with PFS (p = 0.03) and OS (p = 0.002), but VSS was not. Associations with PFS/OS when applying local review vs central review were comparable. CONCLUSIONS: These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials. John Wiley and Sons Inc. 2023-02-17 /pmc/articles/PMC10134372/ /pubmed/36799072 http://dx.doi.org/10.1002/cam4.5628 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle BRIEF COMMUNICATION
Torka, Pallawi
Pederson, Levi D.
Knopp, Michael V.
Poon, David
Zhang, Jun
Kahl, Brad S.
Higley, Howard R.
Kelloff, Gary
Friedberg, Jonathan W.
Schwartz, Lawrence H.
Wilson, Wyndham H.
Leonard, John P.
Bartlett, Nancy L.
Schöder, Heiko
Ruppert, Amy S.
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title_full Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title_fullStr Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title_full_unstemmed Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title_short Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
title_sort is local review of positron emission tomography scans sufficient in diffuse large b‐cell lymphoma clinical trials? a calgb 50303 analysis
topic BRIEF COMMUNICATION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134372/
https://www.ncbi.nlm.nih.gov/pubmed/36799072
http://dx.doi.org/10.1002/cam4.5628
work_keys_str_mv AT torkapallawi islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT pedersonlevid islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT knoppmichaelv islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT poondavid islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT zhangjun islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT kahlbrads islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT higleyhowardr islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT kelloffgary islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT friedbergjonathanw islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT schwartzlawrenceh islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT wilsonwyndhamh islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT leonardjohnp islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT bartlettnancyl islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT schoderheiko islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis
AT ruppertamys islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis